Chase Pharmaceuticals Corporation   Report issue

For profit Phase 2
Founded: Washington D.C. United States (2007)
Status: Acquired by Allergan PLC (2015) (2016) → now AbbVie (2019)

Organization Overview

First Clinical Trial
2014
NCT02185053
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CHASE CHEM | CHASE LABS NJ

Active Ingredients

Marketed Drugs (3)

ergocalciferol (drisdol)

nifedipine (procardia) (1989)

vitamin a

Drugs in Phase 2 Trials (2)

donepezil (aricept) (4 trials)

solifenacin (vesicare) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Dementia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2